INBX insider transaction filings
Inhibrx Biosciences, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-18. Screen INBX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 10 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 9 legs across 4 filings by 3 insiders — 37,500 shares, $3,999,597 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 5 legs across 2 filings by 1 insider — 2,500 shares, $279,010 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 4.
- Largest priced transaction: purchase of 9,681 shares @ $112.28 ($1,087,001) by Lappe Mark, filed 2026-09-08.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Lappe Mark — Chief Executive Officer, Director | 1 | 6 legs · 25,000 sh · $2,645,399 | — | — |
| Kayyem Jon Faiz — Director | 3 | 2 legs · 10,000 sh · $1,067,580 | — | 1 |
| FORSYTH DOUGLAS — Director | 2 | 1 leg · 2,500 sh · $286,617 | — | 1 |
| MANHARD KIMBERLY — Director | 3 | — | 5 legs · 2,500 sh · $279,010 | 1 |
| Vuori Kristiina MD — Director | 1 | — | — | 1 |
Recent Form 4 filings — Inhibrx Biosciences, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4/A | MANHARD KIMBERLY — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4/A | Vuori Kristiina MD — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4/A | FORSYTH DOUGLAS — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4/A | Kayyem Jon Faiz — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-09-17 | 4 | Kayyem Jon Faiz — Director | Purchase (P): 5,000 @ $100 | EDGAR |
| 2026-09-15 | 4 | MANHARD KIMBERLY — Director | Sale (S): 500 @ $111.78 · Sale (S): 500 @ $110.26 · Sale (S): 500 @ $105.05 | EDGAR |
| 2026-09-10 | 4 | MANHARD KIMBERLY — Director | Sale (S): 500 @ $115.14 · Sale (S): 500 @ $115.80 | EDGAR |
| 2026-09-08 | 4 | Kayyem Jon Faiz — Director | Purchase (P): 5,000 @ $113.52 | EDGAR |
| 2026-09-08 | 4 | FORSYTH DOUGLAS — Director | Purchase (P): 2,500 @ $114.65 | EDGAR |
| 2026-09-08 | 4 | Lappe Mark — Chief Executive Officer, Director | Purchase (P): 5,895 @ $99.29 · Purchase (P): 6,605 @ $100.64 · Purchase (P): 1,100 @ $107.12 · Purchase (P): 500 @ $108.23 · Purchase (P): 1,219 @ $111.88 · Purchase (P): 9,681 @ $112.28 | EDGAR |
| 2026-06-04 | 4 | Vuori Kristiina MD — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Kayyem Jon Faiz — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | FORSYTH DOUGLAS — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | MANHARD KIMBERLY — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-04-27 | 4 | Matly David — President | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-10-09 | 4 | VIKING GLOBAL INVESTORS LP — 10% owner Viking Global Opportunities Parent GP LLC — 10% owner Viking Global Opportunities GP LLC — 10% owner Viking Global Opportunities Portfolio GP LLC — 10% owner Viking Global Opportunities Illiquid Investments Sub-Master LP — 10% owner HALVORSEN OLE ANDREAS — 10% owner Ott David C. — 10% owner Shabet Rose Sharon — 10% owner | Sale (S): 308,643 @ $32.25 · Sale (S): 16,315 @ $32.25 · Sale (S): 25,042 @ $32.25 | EDGAR |
| 2025-05-29 | 4 | Vuori Kristiina MD — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-05-29 | 4 | Kayyem Jon Faiz — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-05-29 | 4 | FORSYTH DOUGLAS — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-05-29 | 4 | MANHARD KIMBERLY — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Matly David — President | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Deck Kelly — Chief Financial Officer | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-03-28 | 4 | Kayyem Jon Faiz — Director | Gift (G): 90,000 @ $0 | EDGAR |
| 2024-12-17 | 4 | Kayyem Jon Faiz — Director | Gift (G): 500,000 @ $0 · Gift (G): 250,000 @ $0 · Gift (G): 250,000 @ $0 | EDGAR |
| 2024-12-06 | 4 | Kayyem Jon Faiz — Director | Gift (G): 52,000 @ $0 | EDGAR |
| 2024-11-22 | 4 | Kayyem Jon Faiz — Director | Purchase (P): 34,843 @ $14.23 · Purchase (P): 34,843 @ $14.23 · Purchase (P): 18,750 @ $14.19 · Purchase (P): 18,750 @ $14.19 | EDGAR |
| 2024-10-07 | 4 | Vuori Kristiina MD — Director | Purchase (P): 6,667 @ $15 | EDGAR |
| 2024-09-16 | 4 | Lappe Mark — Chief Executive Officer, Director | Purchase (P): 26,963 @ $15.05 · Purchase (P): 13,037 @ $17.13 | EDGAR |
| 2024-09-12 | 4 | Vuori Kristiina MD — Director | Purchase (P): 179 @ $15 · Purchase (P): 6,457 @ $15.07 | EDGAR |
| 2024-09-10 | 4 | Lappe Mark — Chief Executive Officer, Director | Purchase (P): 26,000 @ $15.29 · Purchase (P): 9,500 @ $15.21 · Purchase (P): 8,500 @ $15.19 | EDGAR |
| 2024-09-03 | 4 | Vuori Kristiina MD — Director | Purchase (P): 7,140 @ $14 | EDGAR |
| 2024-09-03 | 4 | Lappe Mark — Chief Executive Officer, Director | Purchase (P): 10,000 @ $14.03 · Purchase (P): 10,000 @ $14.02 · Purchase (P): 15,288 @ $15.66 · Purchase (P): 4,712 @ $16.31 | EDGAR |
| 2024-08-30 | 4 | MANHARD KIMBERLY — Director | Purchase (P): 10,000 @ $13.98 | EDGAR |
| 2024-08-26 | 4 | FORSYTH DOUGLAS — Director | Purchase (P): 15,188 @ $12.89 · Purchase (P): 59,812 @ $14.07 | EDGAR |
| 2024-08-22 | 4 | Lappe Mark — Chief Executive Officer, Director | Purchase (P): 27,055 @ $12.97 · Purchase (P): 12,945 @ $12.93 | EDGAR |
| 2024-06-24 | 4 | Kayyem Jon Faiz — Director | Gift (G): 89,050 @ $0 · Gift (G): 10,000 @ $0 · Gift (G): 10,000 @ $0 | EDGAR |
| 2024-06-07 | 4 | Kayyem Jon Faiz — Director | Purchase (P): 49,284 @ $17.23 · Purchase (P): 8,265 @ $17.89 | EDGAR |
| 2024-06-04 | 4 | Kayyem Jon Faiz — Director | Purchase (P): 70,193 @ $16.14 · Purchase (P): 46,792 @ $16.61 · Purchase (P): 80,738 @ $17.90 · Purchase (P): 65,337 @ $17.44 · Purchase (P): 23,726 @ $18.24 | EDGAR |
| 2024-06-03 | 4 | VIKING GLOBAL INVESTORS LP — 10% owner Viking Global Opportunities Parent GP LLC — 10% owner Viking Global Opportunities GP LLC — 10% owner Viking Global Opportunities Portfolio GP LLC — 10% owner Viking Global Opportunities Illiquid Investments Sub-Master LP — 10% owner HALVORSEN OLE ANDREAS — 10% owner Ott David C. — 10% owner Shabet Rose Sharon — 10% owner | Other (J): 6,305,866 @ $30 · Other (J): 333,333 @ $30 · Other (J): 511,627 @ $30 · Other (J): 1,038,765 (derivative) @ $30 | EDGAR |
| 2024-05-31 | 4 | Inhibrx, Inc. — 10% owner | Other (J): 13,316,140 | EDGAR |
| 2024-05-30 | 4 | Eckelman Brendan P. — Chief Scientific Officer | Sale (S): 300,000 @ $34.30 · Disposition to issuer (D): 1,735,553 @ $30 · Disposition to issuer (D): 160,000 @ $30 · Disposition to issuer (D): 160,000 @ $30 · Disposition to issuer (D): 6,667 (derivative) · Disposition to issuer (D): 26,667 (derivative) | EDGAR |
| 2024-05-30 | 4 | Deck Kelly — Chief Financial Officer | Disposition to issuer (D): 9,167 (derivative) · Disposition to issuer (D): 14,583 (derivative) · Disposition to issuer (D): 21,250 (derivative) | EDGAR |
| 2024-05-30 | 4 | Vuori Kristiina MD — Director | Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 30,000 (derivative) | EDGAR |
| 2024-05-30 | 4 | Kayyem Jon Faiz — Director | Disposition to issuer (D): 3,224,301 @ $30 · Disposition to issuer (D): 25,000 @ $30 · Disposition to issuer (D): 25,000 @ $30 · Disposition to issuer (D): 17,259 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · +1 more | EDGAR |
| 2024-05-30 | 4 | Lappe Mark — Chief Executive Officer, Director | Disposition to issuer (D): 2,486,192 @ $30 · Disposition to issuer (D): 500,000 @ $30 · Disposition to issuer (D): 59,462 @ $30 · Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 145,000 (derivative) | EDGAR |
| 2024-05-30 | 4 | FORSYTH DOUGLAS — Director | Disposition to issuer (D): 598,257 @ $30 · Disposition to issuer (D): 17,259 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) | EDGAR |
| 2024-05-30 | 4 | MANHARD KIMBERLY — Director | Disposition to issuer (D): 3,500 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 17,259 (derivative) | EDGAR |
| 2024-05-24 | 4 | Eckelman Brendan P. — Chief Scientific Officer | Option exercise (M): 2,510 (derivative) @ $34.12 · Option exercise (M): 2,500 (derivative) @ $34.12 | EDGAR |
| 2024-05-08 | 4 | Deck Kelly — Chief Financial Officer | Option exercise (M): 17,624 (derivative) @ $34.24 · Option exercise (M): 2,087 (derivative) @ $34.24 | EDGAR |
| 2024-03-28 | 4 | Deck Kelly — Chief Financial Officer | Option exercise (M): 396 (derivative) @ $35.40 · Option exercise (M): 416 (derivative) @ $35.40 · Option exercise (M): 1,459 (derivative) @ $35.40 · Option exercise (M): 625 (derivative) @ $35.40 | EDGAR |
Recent 8-K events — Inhibrx Biosciences, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-08 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-15 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-03 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-11 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-21 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-19 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-23 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=INBX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →